phosphoglucomutase 2 like 1Genealiases: BM32A · NEDHFS · PMMLP
Q-omics provides the consensus-scored PGM2L1 profile across patient tissues and cancer cell-line models. PGM2L1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PGM2L1 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, PGM2L1 RNA expression shows 20,570 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, LUAD, and UVM as cancer lineages where PGM2L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGM2L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGM2L1 survival associations across molecular data types. PGM2L1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGM2L1 RNA expression–survival associations across cancer types. High PGM2L1 expression shows unfavorable associations in MESO, ACC, BLCA, LIHC and STAD, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PGM2L1 RNA expression.
This table summarizes PGM2L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PGM2L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGM2L1 shows higher tumor expression in LUAD, KIRC, HNSC, STAD, KIRP and LUSC. The LUAD box plot shows higher PGM2L1 RNA expression in tumor versus normal tissue (log2 FC = +2.580, t-test p < 0.001).
This table shows molecular features associated with PGM2L1 in patient tissues and cancer cell lines. In patient samples, PGM2L1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PGM2L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
